Decitabine

0:43
MDS novel agents & HMAs
David Steensma
1:02
The stages and treatments for myelodysplastic syndromes
Alan List
2:07
International ABNL-MARRO trial for MDS/MPN overlap syndromes
Valeria Santini
2:57
Promising venetoclax updates in AML: DEC10-VEN, CLAD/LDAC, antifungals
Marina Konopleva
2:07
Onvansertib with cytarabine or decitabine for R/R AML
Amer Zeidan
3:35
Onvansertib with cytarabine or decitabine for R/R AML
Amer Zeidan
4:09
QuANTUM-R: quizartinib looks promising for FLT3-ITD mutated AML
Naval Daver
2:38
MPN updates: personalized prognostication, novel treatments & more
Ruben Mesa
1:48
A new era for elderly AML patients
Farhad Ravandi
3:32
Venetoclax in AML updates: approval & combinations
Marina Konopleva
2:45
Identifying genetic mutations for diagnosing MDS
Torsten Haferlach
5:06
Personalized therapy for MDS: Advancements and the future
Torsten Haferlach
1:34
The importance of quickly spotting the signs of AML
Srdan Verstovsek
4:19
Intervening on time: how hypomethylating agents can prevent transition to AML
Srdan Verstovsek
3:20
Venetoclax combinations effective in elderly AML
Marina Konopleva
2:57
Genetic biomarkers of response to venetoclax in AML
Marina Konopleva
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals